Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

STABILITY PROGRAMS FOR BIOTECHNOLOGY PRODUCTS

This article was originally published in The Gold Sheet

Executive Summary

...may require a reassessment of development and early clinical materials to understand the significance of process, product and analytical changes made later, FDA and industry experts are cautioning. At a "CMC strategy forum" on biotech product stability, participants explored the intimate web of relationships between the analytical work done in the development phase and a viable stability program on the commercial product. Producing and retaining enough material during the earlier phases is among the ways firms must plan ahead if the program objectives are going to be achieved. Challenging issues for biotech products include: - how to set reasonable stability targets in the early clinical phases - the role of stability assessments in change control - the implications of non-conforming results, and - how to incorporate new information as assays improve. [Included are presentations from the stability strategy forum on the role of stress studies in the development process, setting up a stability program in the late clinical/application phase, and post-marketing issues].

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel